Cardiol Therapeutics Releases Phase II Data Showing CardiolRx Reduces Pericarditis Pain and Inflammation | TSX:CRDL, NASDAQ:CRDL

Proactive InvestorsJun 13 08:08 ET

Cardiol Therapeutics Announces Positive Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx also shown to reduce inflammation in patients with elevated CRP89% of patients have

newsfileJun 13 07:58 ET

Sector Spotlight: Orphan Drug Developers With Significant Upside

Stockhouse Jun 3 07:00 ET

Cardiol Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

Cardiol Therapeutics Inc. Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 23 11:48 ET

Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure

Cardiol Therapeutics (CRDLTO) working on treatments for heart disease, on Tuesday said its Phase II trial evaluating the impact of CardiolRx on myocardial recovery in patients with acute myocarditis (

MT NewswiresMay 14 11:30 ET

Cardiol Therapeutics Surpasses 85% Enrollment in ARCHER Trial for Acute Myocarditis | TSX:CRDL, NASDAQ:CRDL

Proactive InvestorsMay 14 05:37 ET